Hypertension, a major risk factor for cardiovascular disease worldwide, is increasing significantly in urbanised South Africans. Impaired glomerular filtration is a potential contributor to hypertension. Although HIV infection is widespread, little is known regarding its contribution to diminished estimated glomerular filtration rate (eGFR) and, in turn, hypertension in Africans. We compared eGFRs and cardiovascular profiles of newly identified HIV infected African men (N ¼ 53) not yet undergoing anti-retroviral therapy, and uninfected African men of similar age and anthropometry. The aim of the study was to determine whether eGFR is diminished in treatment naive HIV infected individuals and whether eGFR is associated with a potential modulator of hypertension, namely serum L-arginine. Cardiovascular risk factor profiles of HIV infected and uninfected men were similar. In men with healthy eGFRs 490 ml min À 1 per 1.73 m 2 , eGFR was significantly lower with HIV infection (114 (90; 147)) compared with that in uninfected men: (120 (91; 168)), P ¼ 0.043. Despite the absence of clinically-diagnosed renal dysfunction, eGFR associated significantly with serum L-arginine only in HIV infected men (R 2 ¼ 0.277, b ¼ À 0.299, P ¼ 0.034), whereas L-arginine did not stay in the model for uninfected men. This difference suggests that the fate of L-arginine as a substrate for nitric oxide generation may be altered in HIV infected individuals. Subsequently this is likely to escalate endothelial dysfunction, contributing to later hypertension and cardiovascular disease. Our findings show that while glomerular filtration rate is not associated with L-arginine in uninfected men, it is diminished and significantly negatively associated with serum L-arginine in HIV infected men.
INTRODUCTION
Although historically not common in Africans, cardiovascular disease (CVD) is now an integral part of urbanization in Africans. 1 CVD develops earlier in Afro-Americans than in Caucasians and a higher proportion of Afro-Americans suffer from end-stage renal disease. 2, 3 Although hypertension may cause renal failure, 1 equally, renal dysfunction may induce hypertension. 4, 5 A diminution of estimated glomerular filtration rate (eGFR) increases the risk of hypertension in individuals without clinically recognized kidney dysfunction. 6 Hypertension, a major risk for CVD 7, 8 is frequently induced by reduced bioavailability of L-arginine derived nitric oxide (NO), which characterizes endothelial dysfunction. 9 In vascular endothelium, endothelial NO synthase generates NO (from L-arginine), which diffuses into vascular smooth muscle cells where it mitigates contractility and ultimately vascular tone. Because there is no alternative substrate for NO production, a deficiency in L-arginine will impair NO availability, emphasizing its unique importance to vascular health. 10 eGFR is partially regulated by NO. 11 In addition, endogenous derivates of L-arginine, asymmetric dimethyl arginine and symmetric dimethylarginine (SDMA) inhibit vascular bioavailability of NO. 12, 13 The percentage of the South African population infected with HIV is one of the largest worldwide.
14 HIV increases the risk of cardiovascular disease 15 by inducing inflammatory reactivity in the vasculature thereby contributing to vascular damage and endothelial dysfunction. 16 Hypertension was associated with HIV-related renal dysfunction in infected individuals before anti-retroviral therapy became widespread. 17 By inducing renal vascular damage, HIV is likely to reduce eGFR. Literature on the hypertensive influence of HIV alone is scarce because currently, highly active antiretroviral therapy is prescribed as soon as a low CD4 count HIV infection is diagnosed. We therefore compared the cardiovascular risk profiles and eGFR, of treatment naive African men free of HIV and men infected with the virus. None of them were clinically diagnosed with chronic kidney disease or HIV associated nephropathy. We hypothesized that (1) there is a subclinical influence of HIV on glomerular filtration and L-arginine utilization in South African men; (2) evident as a differential association of eGFR and L-arginine in HIV infected and uninfected individuals. The objective of the study was to determine whether eGFR (a risk factor for hypertension) tended to diminish in treatment naive HIV infected individuals and whether this is associated with a potential modulator of hypertension, serum L-arginine.
MATERIALS AND METHODS

Study design and subject selection
We collected data during the South African study regarding the Influence of Sex, Age and Ethnicity on Insulin sensitivity and Cardiovascular function 1 Hypertension in Africa Research Team, North-West University, Potchefstroom, South Africa and (the SAfrEIC study). In the present substudy we included male African volunteers (20-70 years old) living in urban areas of the North West Province of South Africa. A total of 130 men were not infected with the HIV virus, whereas 53 were newly identified as infected with HIV and therefore had not used anti-retroviral therapy (treatment naive).
Exclusion criteria included symptoms indicating illness such as headache or fever, renal and hepatic dysfunction (jaundice) or previous diagnosis of any serious chronic disease (except hypertension) for example, diabetes (n ¼ 2). None of the participants used highly active anti-retroviral therapy or anti-hypertensive medication. Few participants were obese; body mass index (kg m À 2 ) exceeded 25 in less than 8% and 7.8% of infected individuals and uninfected individuals, respectively. This study was approved by the North-West University's Ethics Committee (Potchefstroom campus) in line with the Declaration of Helsinki revised in 2008. Informed written consent was obtained from all participants after procedures had been explained to them in their home language.
Organizational procedures
Starting at 0700 h, participants were examined clinically within the North West University Potchefstroom campus's Metabolic Unit. Basic health and demographic questionnaires were completed and anthropometric measurements taken for each individual. Fasting blood samples (brachial vein) were taken by a registered nurse followed by cardiovascular measurements. Each participant was given a full breakfast and financial compensation for travel expenses. They also received feedback on their health status and were referred to their local physician, clinic or hospital if any irregularities (for example, in blood pressure) were encountered.
Biochemical analyses
Participants fasted overnight before blood samples were taken (1000 h). Samples were separated into plasma and serum aliquots which were stored at À 80 1C. As a screen for diabetes mellitus a LifeScan Surestep Blood Glucose Monitoring System (LifeScan Inc., Milputas, CA 9535, USA) was used to measure capillary blood glucose. A Konelab auto-analyzer (Thermo Fisher Scientific Oy, Vantaa, Finland) was used to determine gglutamyl transferase, lipids, C-reactive protein (hsCRP), serum blood glucose and creatinine. Estimated creatinine clearance was assessed using the Cockcroft-Gault formula 18 and adjusted for body surface area, to determine the eGFR. An enzyme immunoassay (Diagnostic Reagents, Inc., Sunnyvale, CA, USA) and a Roche modular analyzer (Roche, Basel, Switzerland) was used to measure plasma cotinine. Insulin was determined using an immunoenzymometric assay (ST AIA-PACK IRI kit, cat. No. 025260). The homeostasis model index assessment was calculated as the product of the fasting serum concentrations of glucose and insulin divided by 22.5. HIV status was determined with the First Response test haemaglutination assay (PMC Medical, Daman, India) immediately after venisection and confirmed with the Pareeshak test (BHAT Bio-tech, Bangalore, India). A fully validated high throughput LC-MS/MS assay was used for mass spectrometric determinations of symmetric dimethyl arginine (SDMA), asymmetric dimethyl arginine and L-arginine as described elsewhere. 19, 20 A spectrophotometric assay, where 1.0 mg l 
Cardiovascular measurements
Systolic and diastolic blood pressures (BP cuff on left arm) were measured with the OMRON HEM-757 apparatus (Omron Healthcare, Kyoto, Japan) after a 10 min rest period in a seated position. Following another 5 min at rest, the measurement was repeated. The Complior SP device (Artech Medical, Pantin, France) was used to measure non-invasively accessible superficial pulses in a musculo-elastic mixed arterial segment (carotiddorsalis pedis) to determine pulse wave velocity as a measure of arterial stiffness. The measurement was taken from the left side of each subject in the supine position. Arterial compliance (Windkessel) (Cw) was determined using a Finometer device (Finapres Measurement Systems, Amsterdam,the Netherlands). This instrument calculates this cardiovascular parameter from aortic-flow waveform derived from finger arterial blood pressure measured non-invasively. 23 
Statistical analyses
Statistical analysis was performed with Statistica, version 10 (StatSoft, Inc., Tulsa, OK, USA). Variables with skewed distributions were normalized by logarithmic transformation. The central tendency and spread of logarithmically transformed variables were represented by the geometric mean and the 5th-95 percentile interval. Two sampled independent t tests were used to compare means. Using single regressions and multiple linear regressions we investigated associations between eGFR and cardiovascular variables in HIV infected and uninfected men. A stepwise regression procedure was used to estimate the contribution of independent parameters to the variability of eGFR.
RESULTS
Characteristics of participants
We compared the general characteristics and cardiovascular profiles of HIV infected and uninfected African men (Table 1) . Cardiovascular measurements showed no differences but serum creatinine, hsCRP, ROS and total serum protein were significantly increased in HIV infected men, while HDL and serum albumin were significantly lower (Po0.05). Serum L-arginine concentrations did not differ significantly between the two groups. Neither estimated creatinine clearance nor eGFR were significantly different when each cohort tested included men with mild renal insufficiency (eGFRo90 ml min À 1 per 1.73 m 2 ).
Sensitivity analysis However, when we restricted our comparisons to men with eGFRs above 90 ml min À 1 per 1.73 m 2 , the average eGFRs were 115.1 (117.0; 124.8) and 104.6 (101.0; 108.5) ml min À 1 per 1.73 m 2 for uninfected (N ¼ 109) and HIV infected men (N ¼ 50), respectively (P ¼ 0.043). The cutoff value of 90 ml min À 1 per 1.73 m 2 was chosen because it is a widely accepted clinical reference value for first stage kidney disease and does not exclude potentially mildly reduced eGFR 24 from 'normal' eGFR for which no value is specified.
Linear regression analyses Unadjusted correlations of eGFR with cardiovascular dysfunction were performed. Correlation patterns were substantially different in both groups (Table 2 ). In the HIV infected men only, eGFR correlated with total serum protein (r ¼ À 0.357, P ¼ 0.029), ROS (r ¼ À 0.311, P ¼ 0.029) and L-arginine (r ¼ À 0.334, P ¼ 0.016), respectively. Figure 1a illustrates the different trends in the associations of eGFR with L-arginine in each cohort irrespective of eGFR. Exploratory analysis of eGFRs greater than 90 ml min À 1 per 1.73 m 2 , plotted by quartiles of L-arginine is shown in Figure 1b with P representing the trend in each analysis.
Multiple regression analysis Significant correlations with log eGFR identified total serum protein, ROS and L-arginine as independent variables for forward stepwise multiple regression analysis with log eGFR as the dependent variable (Table 3 ). In addition, hsCRP was selected as an independent variable because serum concentrations were significantly higher in the HIV infected group and hsCRP has been reported as a prognostic marker for mortality in HIV infection. 25 Of the four independent variables, only the associations of L-arginine and hsCRP with log eGFR were significant in the HIV infected group (b ¼ À 0.299, P ¼ 0.034 and b ¼ À 0.322, P ¼ 0.029, respectively, R 2 ¼ 0.277). L-arginine contributed 21.8% of the variability in log eGFR and was the only significant contributor of the four variables. In contrast, the association of log eGFR with L-arginine in the model of uninfected participants was not significant. In addition, associations between log eGFR and total serum protein, ROS and hsCRP were also not significant; the R 2 value attributable to all four markers was 0.029 in the uninfected model. However, when analysis excluded individuals with an eGFR below 90 ml min
, the relationship between L-arginine and log eGFR strengthened (b ¼ À 0.430, R 2 ¼ 0.250, P ¼ 0.005) only in the HIV infected group. The relationship between log eGFR and hsCRP weakened and was no longer significant. Shown in Table 2 , log eGFR correlated with log g-glutamyl transferase but not cotinine in HIV infected individuals unless eGFR values below 90 ml min À 1 per 1.73 m 2 were excluded. In this case, both cotinine and log g-glutamyl transferase correlated with log eGFR (only in infected men). For this reason, multiple regression analysis was carried out (in men with eGFRs above 90 ml min À 1 per 1.73 m 2 ) with and without cotinine and log g-glutamyl transferase as independents. The results of the three different models are shown in Table 3b . When both were included in the same model (model 3) the association of log eGFR with L-arginine increased (b ¼ À 0.500, R 2 ¼ 0.266, P ¼ 0.001).
DISCUSSION
This exploratory study investigated the possibility that (1) HIV potentiates the development of hypertension and cardiovascular disease by influencing endothelial function, which correlates with diminished glomerular filtration and (2) the association of eGFR with L-arginine in HIV infected individuals is significantly different from that in uninfected participants. We found that eGFR was significantly associated with serum L-arginine, a NO precursor, in men infected with HIV only when compared with that in men without HIV infection. Adequately functioning endothelium converts L-arginine to NO, a prominent vasodilator and regulator of vascular tone, which is implicated in the maintenance of normotension.
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Although creatinine clearance and eGFR were not different in the two cohorts, a significantly increased serum creatinine concentration existed in the HIV infected group. In addition, when men with an eGFR below 90 ml min À 1 per 1.73 m 2 were excluded from the analysis (N ¼ 19) , a significantly lower eGFR was detected in HIV infected men, indicating a potential alteration of glomerular filtration; putatively a hypertensive influence and therefore an increased risk for future cardiovascular disease. 16 A large proportion of HIV infections were newly diagnosed and were therefore antiretroviral treatment naive in our exploratory study. This provided us with the unique opportunity to study the effects of the virus without the metabolic and other effects of antiretroviral therapy. The results are not directly clinically relevant because most infected individuals would receive treatment for the condition.
Correlations of eGFR with ROS, L-arginine and SDMA are reminiscent of reports that ROS and SDMA, a derivative of L-arginine, are involved in the regulation of NO generation. 13, 26 SDMA inhibits NO generation but L-arginine does not. However, in contrast to the significant correlation with SDMA in men without HIV infection, eGFR did not correlate with SDMA in the HIV infected group, suggesting a deviation from the utilization of L-arginine (or regulation thereof) which occurs in men without HIV infection.
Consistently throughout our analyses, eGFR correlated negatively with L-arginine in HIV infected men but not in uninfected men (as shown in Figure 1 ). This complements the significant positive association of L-arginine with eGFR found by Lü neburg in healthy Caucasians. 29 In addition, in a comparison of HIV infected and uninfected men who were not clinically diagnosed as renally dysfunctional that is, with eGFR values greater than 90 ml min À 1 per 1.73 m 2 , the dependent association of eGFR with L-arginine strengthened in the HIV infected cohort. In conjunction with the lower eGFR values in the HIV infected men, this suggests that asymptomatic HIV infection affects glomerular filtration per se and that it is associated with altered L-arginine status.
L-arginine is a precursor for the synthesis of creatinine, many proteins, urea, glutamate, polyamines, agmatine and proline in addition to NO 28 making it difficult to identify mechanistic changes in its utilization. However, it is reasonable to speculate that it may involve, albeit limited, renal damage if the association of L-arginine with glomerular filtration is altered. Our study has shown that L-arginine is negatively associated with eGFR in HIV infected African men in contrast to an absence of any association of eGFR with L-arginine in African men without HIV infection. Furthermore, in our study, the average serum L-arginine, asymmetric dimethyl arginine and the L-arginine to asymmetric dimethyl arginine ratio were considerably greater in HIV infected and uninfected men than those found in healthy Caucasians. 29 This implies an ethnically predicted variation in baseline concentrations of these markers which needs to be confirmed by further investigation. In addition, a difference in renal physiology may contribute to the increased prevalence of renal disease associated with African ethnicity. Some evidence suggests that a polymorphism in chromosome 22, inherent with African ancestry, and coding for a nonmuscle myosin variant in podocytes may enhance protection against trypanosome infections while also predisposing to kidney disease. 30 This haplotype occurs only in 4% of Caucasian Americans but in 60% of Afro-Americans, potentially contributing to the hypertensive tendency in this ethnicity. As hypertension and HIV infection are more prevalent in black South Africans (and Afro-Americans) than in South African Caucasians, 1, 31 it is plausible that HIV infection increases this predisposition to hypertension.
It is relevant that administration of L-arginine has been used to attenuate renal dysfunction. 32 Most L-arginine taken up by endothelial cells from the circulation for NO production is synthesized in the proximal tubule of the kidney. 32 In addition, filtered L-arginine is reabsorbed by the proximal tubule. 33 Impairment of the proximal tubule's capacity for L-arginine synthesis or its resorption would reduce the bioavailability of L-arginine. However, other disruptions of L-arginine utilization are possible, including the activity of endothelial NO synthase, which competes with several enzymes for L-arginine as a substrate. 13, 33 This exploratory study should be interpreted within the boundaries of its strengths and limitations. Lifestyle differences may influence the health outcomes between populations from widely differing socio-ecenomic backgrounds. Both cohorts were from a low socio-economic background, from an urban environment and were recruited from the same area. The absence of significant differences in mean body mass index, age, alchohol abuse and smoking and the low prevalence of obesity within each cohort demonstrates their similarity. This suggests that the lifestyle differences between each cohort are likely to be small and that the differences observed in our investigation are less likely to be attributable by differences in lifestyle. However, it is nevertheless possible that lifestyle differences influenced our findings to a limited degree. Our study is limited in that it is exploratory and designed to identify areas of further investigation regarding factors contributing to the increasing prevalence of cardiovascular disease amongst Africans. It is limited by its crosssectional design in that our measurements and analyses have not conclusively identified causes underlying the differences we detected between African men infected with HIV and those who were not. However, the close matching of participants in each cohort and the fact that they were not subjected to retroviral therapy are strengths of this study. In addition, this study contributes to the currently sparse literature available on HIV infection in Africans.
The most important finding of our analysis was the negative association of eGFR with L-arginine only in the HIV infected cohort. The development of cardiovascular disease is accelerated in HIV infected individuals, 15 which is consistent with our evidence suggesting altered arginine utilization in HIV infected individuals. Evidence suggests that long-term use of highly active antiretroviral therapy is associated with renal impairment. 27 However, our results indicate that the virus itself begins to impair kidney function early on, even without retroviral treatment. This implies that renal function should be examined more stringently in HIV infected individuals regardless of whether highly active antiretroviral therapy is clinically justified and prophylactic measures taken from the time of diagnosis before clinical evidence of chronic kidney disease is detected. This may slow the development of symptoms of CVD, such as hypertension, later in their lives. Further experimental investigation is necessary to identify interventions, which will attenuate the progression of cardiovascular disease (and associated renal dysfunction) in HIV infected individuals such as, for example, modifying dietary L-arginine content.
What is already known on this subject
The prevalence of cardiovascular disease is more prevalent in black South Africans than in their Caucasian compatriots. HIV infection enhances the development of cardiovascular and endstage renal diseases.
What this study adds Serum L-arginine is not directly associated with renal function in HIV free black South Africans. However, a negative association of estimated glomerular filtration rate and serum L-arginine occurs without exposure to antiretroviral therapy in HIV infected black South Africans.
Understanding the way that L-arginine is utilized by the vascular endothelium of HIV infected individuals, including that found in the proximal tubules of the kidney will help identify strategies to retard the development of cardiovascular disease and renal deterioration.
